nach oben

Erschienen in:

14.05.2019 | Original Article

TRActional DIabetic reTInal detachment surgery with co-adjuvant intravitreal dexamethasONe implant: the TRADITION STUDY

verfasst von: Matias Iglicki, Dinah Zur, Adrian Fung, Pierre-Henry Gabrielle, Marco Lupidi, Rodrigo Santos, Catharina Busch, Matus Rehak, Zafer Cebeci, Martin Charles, Dua Masarwa, Shulamit Schwarz, Adiel Barak, Anat Loewenstein, for the International Retina Group (IRG)

Erschienen in: Acta Diabetologica | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Aim

Main failure of diabetic tractional retinal detachment (TRD) surgery is the development of proliferative vitreoretinopathy (PVR), causing higher re-detachment rates. We investigated whether the use of dexamethasone (DEX) implant at the end of pars plana vitrectomy (PPV) with silicone oil tamponade might have an impact on these outcomes.

Design

Comparative, nonrandomized, retrospective study.

Participants

A total of 148 eyes from 148 patients that underwent PPV with silicone oil tamponade for diabetic TRD (with DEX implant, n = 52; without DEX implant, n = 96).

Methods

Consecutive patients’ records were reviewed for time between TRD diagnosis and surgery; lens status before surgery and after 6, 12, and 24 months; retina attachment rate after primary PPV; change in postoperative PVR severity; rate of re-detachment at 6, 12, and 24 months; use of IOP lowering treatment after 6, 12, and 24 months; surgery details; intra- and postoperative complications. Correlations between outcome measures, postoperative PVR severity, and re-detachment rates were analyzed.

Main outcome measures

Change in postoperative PVR severity and retinal re-detachment rates with and without the adjuvant use of DEX implant.

Results

Retinal re-detachment rates were significantly higher in the group of patients that did not receive DEX implant [11/96 (11.5%) vs. 0/52 (0%), p = 0.049; 11/84 (12.9%) vs. 4/52 (7.7%), p = 0.007; 14/71 (19.7%) vs. 5/52 (10%) p < 0.001 at 6, 12, and 24 months, respectively]. PVR severity correlated with retinal status at 12 and 24 months (p = 0.018 and p = 0.027, respectively). The difference in PVR severity between the two groups was statistically significant at 6, 12, and 24 months (p < 0.001).

Conclusions

DEX implant at the end of PPV in patients with diabetic TRD improves PVR severity and decreases re-detachment rates. This should be considered as an option in the customized treatment of TRD.

Guariguata L, Whiting DR, Hambleton I et al (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103:137–149CrossRefPubMed

Antonetti DA, Klein R, Gardner TW (2015) Diabetic retinopathy. Med (Baltim) 43:13–19CrossRef

Sternfeld A, Axer-Siegel R, Stiebel-Kalish H et al (2015) Advantages of diabetic tractional retinal detachment repair. Clin Ophthalmol 9:1989–1994CrossRefPubMedPubMedCentral

Dikopf MS, Patel KH, Setlur VJ, Lim JI (2015) Surgical outcomes of 25-gauge pars plana vitrectomy for diabetic tractional retinal detachment. Eye 29:1213–1219CrossRefPubMedPubMedCentral

Storey PP, Ter-Zakarian A, Philander SA et al (2017) Visual and anatomical outcomes after diabetic traction and traction-rhegmatogenous retinal detachment repair. Retina 38:1913–1919CrossRef

Shroff CM, Gupta C, Shroff D et al (2018) Bimanual microincision vitreous surgery for severe proliferative diabetic retinopathy: outcome in more than 300 eyes. Retina 38:S134–S145CrossRefPubMed

El Rami H, Barham R, Sun JK, Silva PS (2017) Evidence-based treatment of diabetic retinopathy. Semin Ophthalmol 32:67–74CrossRefPubMed

Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487CrossRefPubMed

Vujosevic S, Simó R (2017) Local and systemic inflammatory biomarkers of diabetic retinopathy: an integrative approach. Invest Ophthalmol Vis Sci 58:68–75. https://doi.org/10.1167/iovs.17 CrossRef

10.

Funatsu H, Yamashita H, Noma H et al (2005) Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefe’s Arch Clin Exp Ophthalmol 243:3–8CrossRef

11.

Schwartzman ML, Iserovich P, Gotlinger K et al (2010) Profile of lipid and protein autacoids in diabetic vitreous correlates with the progression of diabetic retinopathy. Diabetes 59:1780–1788. https://doi.org/10.2337/db10-0110 CrossRefPubMedPubMedCentral

12.

Goldberg RB (2009) Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 94:3171–3182CrossRefPubMed

13.

dell’Omo R, Semeraro F, Bamonte G et al (2013) Vitreous mediators in retinal hypoxic diseases. Mediat Inflamm 2013:935301

14.

Tang J, Kern TS (2011) Inflammation in diabetic retinopathy. Prog Retin Eye Res 30:343–358CrossRefPubMedPubMedCentral

15.

Iglicki M, Zur D, Busch C et al (2018) Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the ‘DR-Pro-DEX Study’. Acta Diabetol. https://doi.org/10.1007/s00592-018-1117-z CrossRefPubMed

16.

Moon SW, Sun Y, Warther D et al (2018) New model of proliferative vitreoretinopathy in rabbit for drug delivery and pharmacodynamic studies. Drug Deliv 25:600–610. https://doi.org/10.1080/10717544.2018.1440664 CrossRefPubMedPubMedCentral

17.

Hilton G, Machemer R, Michels R, Okun E, Schepens C, Schwartz A (1983) The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 90:121–125CrossRef

18.

Deuchler S, Ackermann H, Singh P et al (2017) Key factors to improve the outcome of retinal reattachment surgery in proliferative vitreoretinopathy and proliferative diabetic retinopathy. J Ophthalmol. https://doi.org/10.1155/2017/2323897 CrossRefPubMedPubMedCentral

19.

Goezinne F, La Heij EC, Berendschot TTJM et al (2007) Risk factors for redetachment and worse visual outcome after silicone oil removal in eyes with complicated retinal detachment. Eur J Ophthalmol 17:627–637CrossRefPubMed

20.

Scott IU, Flynn HW, Murray TG et al (2005) Outcomes of complex retinal detachment repair using 1000- vs 5000-centistoke silicone oil. Arch Ophthalmol 123:473–478. https://doi.org/10.1001/archopht.123.4.473 CrossRefPubMed

21.

Soheilian M, Mazareei M, Mohammadpour M, Rahmani B (2006) Comparison of silicon oil removal with various viscosities after complex retinal detachment surgery. BMC Ophthalmol 6:1–6. https://doi.org/10.1186/1471-2415-6-21 CrossRef

22.

Altan T, Acar N, Kapran Z et al (2008) Transconjunctival 25-gauge sutureless vitrectomy and silicone oil injection in diabetic tractional retinal detachment. Retina 28:1201–1206CrossRefPubMed

23.

Hou H, Huffman K, Rios S et al (2015) A novel approach of daunorubicin application on formation of proliferative retinopathy using a porous silicon controlled delivery system: pharmacodynamics. Invest Ophthalmol Vis Sci 56:2755–2763CrossRefPubMedPubMedCentral

24.

Schaub F, Hoerster R, Schiller P et al (2018) Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial. Trials 19:384CrossRefPubMedPubMedCentral

25.

London NJS, Kaiser RS, Khan MA et al (2018) Determining the effect of low-dose isotretinoin on proliferative vitreoretinopathy: the DELIVER trial. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2018-312839 CrossRefPubMed

26.

Kaneko H, Terasaki H (2017) Biological Involvement of microRNAs in proliferative vitreoretinopathy. Transl Vis Sci Technol 6:5CrossRefPubMedPubMedCentral

27.

Bhaskaranand M, Ramachandra C, Bhat S et al (2016) Automated diabetic retinopathy screening and monitoring using retinal fundus image analysis. J Diabetes Sci Technol 10:254–261. https://doi.org/10.1177/1932296816628546 CrossRefPubMedPubMedCentral

28.

Banerjee PJ, Quartilho A, Bunce C et al (2017) Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial. Ophthalmology 124:757–767CrossRefPubMed

29.

Moysidis SN, Thanos A, Vavvas DG (2012) Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. Mediat Inflamm 2012:815937CrossRef

30.

Pastor JC, Rojas J, Pastor-Idoate S et al (2016) Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res 51:125–155CrossRefPubMed

31.

Chen W, Chen H, Hou P et al (2011) Midterm results of low-dose intravitreal triamcinolone as adjunctive treatment for proliferative vitreoretinopathy. Retina 31:1137–1142CrossRefPubMed

32.

Cheema RA, Peyman GA, Fang T et al (2007) Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging 38:365–370CrossRef

Titel: TRActional DIabetic reTInal detachment surgery with co-adjuvant intravitreal dexamethasONe implant: the TRADITION STUDY
verfasst von: Matias Iglicki
Dinah Zur
Adrian Fung
Pierre-Henry Gabrielle
Marco Lupidi
Rodrigo Santos
Catharina Busch
Matus Rehak
Zafer Cebeci
Martin Charles
Dua Masarwa
Shulamit Schwarz
Adiel Barak
Anat Loewenstein
for the International Retina Group (IRG)
Publikationsdatum: 14.05.2019
Verlag: Springer Milan
Erschienen in: Acta Diabetologica / Ausgabe 10/2019
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-019-01357-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aim

Design

Participants

Methods

Main outcome measures

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2019

Placental expressions and serum levels of adiponectin, visfatin, and omentin in GDM

The impact of diabetes mellitus on clinical outcomes following chemotherapy for the patients with pancreatic cancer: a meta-analysis

Systematic review: associations of calcium intake, vitamin D intake, and physical activity with skeletal outcomes in people with Type 1 diabetes mellitus

Pancreatic perfusion and its response to glucose as measured by simultaneous PET/MRI

Can internet search engine queries be used to diagnose diabetes? Analysis of archival search data